Caribou Biosciences (CRBU) Change in Accured Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Change in Accured Expenses data on file, last reported at -$2.6 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 14.67% year-over-year to -$2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.9 million (down 575.75% YoY) and the FY2025 annual result came in at -$6.3 million, down 397.09% from the prior year.
• Change in Accured Expenses advanced to -$2.6 million in Q1 2026 per CRBU's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.0 million in Q2 2024 and bottomed at -$4.1 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is -$1.1 million (2025), against an average of -$74933.3.
• The widest annual swing landed in 2022, when Change in Accured Expenses surged 198.12%; it then tumbled 176.23% in 2024.
• Tracing CRBU's Change in Accured Expenses over 5 years: stood at $2.8 million in 2022, then gained by 2.81% to $2.9 million in 2023, then plunged by 176.23% to -$2.2 million in 2024, then fell by 27.59% to -$2.8 million in 2025, then gained by 6.04% to -$2.6 million in 2026.
• Per Business Quant, the three latest CRBU Change in Accured Expenses figures stand at -$2.6 million (Q1 2026), -$2.8 million (Q4 2025), and -$1.1 million (Q3 2025).

Peer Comparison